---
title: "GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit"
id: "medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions"
canonical_url: "https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Medical News Today"
source_url: "https://www.medicalnewstoday.com/articles/can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions/"
published_at: "2026-08-26T10:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Medical News Today
- **Source URL:** [Original Journal Publication](https://www.medicalnewstoday.com/articles/can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions/)
- **Published At:** 2026-08-26T10:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Recent research suggests **GLP-1 receptor agonists (GLP-1s)**, drugs used for type 2 diabetes and obesity, might improve metabolic and reproductive features in people with polyendocrine metabolic ovarian syndrome (PMOS), formerly PCOS. - A small July 2026 semaglutide study of 96 individuals with PMOS and BMI >25 kg/m2 reported menstrual cycle regulation in 95% of those with overweight or mild obesity after 6 months; only 25% with moderate or severe obesity saw the same effect. - A February 2026 systematic review and meta-analysis of 17 articles (11 randomized controlled trials) concluded GLP-1s reliably induce weight loss in people with PMOS who are overweight/obese, but effects on other metabolic and reproductive outcomes remain uncertain. - Clinical experts warn evidence is mixed and of low to very low certainty due to small, heterogeneous trials; GLP-1 RAs are not endorsed as first-line or universal therapy for PMOS. - Mechanistic rationale: PMOS involves hyperandrogenism and hyperinsulinemia; weight loss and improved insulin sensitivity from GLP-1s can raise SHBG, reduce ovarian androgen production, correct peripheral estrogen excess from adipose tissue, and potentially restore ovulation. - Who may benefit: individuals with PMOS who also have overweight or obesity are the likeliest candidates. Thin phenotypes of PMOS may not benefit and often respond to lifestyle measures alone. - Safety and practical cautions: GLP-1s carry common gastrointestinal adverse effects; they are contraindicated for people planning conception because of teratogenicity concerns and may reduce oral contraceptive efficacy (notably tirzepatide). - Research gaps: need for well-designed, PMOS-specific, phenotype-stratified trials to determine long-term reproductive, metabolic, and safety outcomes before guideline recommendations change.
## Clinical Analysis & Structured Key Points
[Medical News Today](https://www.medicalnewstoday.com/) * Health Conditions Health Conditions * [Alzheimer's & Dementia](https://www.medicalnewstoday.com/alzheimers-and-dementia) * [Anxiety](https://www.medicalnewstoday.com/anxiety) * [Asthma & Allergies](https://www.medicalnewstoday.com/asthma-and-allergies) * [Atopic Dermatitis](https://www.medicalnewstoday.com/program/investigating-atopic-dermatitis) * [Breast Cancer](https://www.medicalnewstoday.com/breast-cancer) * [Cancer](https://www.medicalnewstoday.com/cancer) * [Cardiovascular Health](https://www.medicalnewstoday.com/cardiovascular-health) * [COVID-19](https://www.medicalnewstoday.com/coronavirus?correlationId=2b137d5a-dcfb-464e-9ea6-72c5a54b4e92) * [Diabetes](https://www.medicalnewstoday.com/diabetes) * [Endometriosis](https://www.medicalnewstoday.com/endometriosis) * [Environment & Sustainability](https://www.medicalnewstoday.com/environment-and-sustainability) * [Exercise & Fitness](https://www.medicalnewstoday.com/exercise-and-fitness) * [Eye Health](https://www.medicalnewstoday.com/eye-health) * [Headache & Migraine](https://www.medicalnewstoday.com/headache-and-migraine) * [Health Equity](https://www.medicalnewstoday.com/health-equity) * [HIV & AIDS](https://www.medicalnewstoday.com/hiv-and-aids) * [Human Biology](https://www.medicalnewstoday.com/human-biology) * [Leukemia](https://www.medicalnewstoday.com/leukemia) * [LGBTQIA+](https://www.medicalnewstoday.com/LGBTQIA) * [Men's Health](https://www.medicalnewstoday.com/mens-health) * [Mental Health](https://www.medicalnewstoday.com/mental-health) * [Multiple Sclerosis (MS)](https://www.medicalnewstoday.com/multiple-sclerosis) * [Nutrition](https://www.medicalnewstoday.com/nutrition) * [Parkinson's Disease](https://www.medicalnewstoday.com/parkinsons-disease) * [Psoriasis](https://www.medicalnewstoday.com/psoriasis) * [Sexual Health](https://www.medicalnewstoday.com/sexual-health) * [Ulcerative Colitis](https://www.medicalnewstoday.com/program/investigating-ulcerative-colitis) * [Women's Health](https://www.medicalnewstoday.com/womens-health) * Health Products Health Products [All](https://www.medicalnewstoday.com/products-and-reviews) * [Nutrition & Fitness](https://www.medicalnewstoday.com/products-and-reviews/nutrition-and-fitness-products) * [Vitamins & Supplements](https://www.medicalnewstoday.com/products-and-reviews/vitamin-and-supplement-products) * [CBD](https://www.medicalnewstoday.com/products-and-reviews/cbd-products) * [Sleep](https://www.medicalnewstoday.com/products-and-reviews/sleep-products) * [Mental Health](https://www.medicalnewstoday.com/products-and-reviews/mental-health-services-and-products) * [At-Home Testing](https://www.medicalnewstoday.com/products-and-reviews/at-home-testing-products) * [Men’s Health](https://www.medicalnewstoday.com/products-and-reviews/mens-health-products) * [Women’s Health](https://www.medicalnewstoday.com/products-and-reviews/womens-health-products) * Discover News * [Latest News](https://www.medicalnewstoday.com/news) * [Medicare 2026 Costs](https://www.medicalnewstoday.com/articles/medicare-costs-3-key-changes-in-2026) Original Series * [Medical Myths](https://www.medicalnewstoday.com/content-series/medical-myths) * [Honest Nutrition](https://www.medicalnewstoday.com/content-series/honest-nutrition) * [Through My Eyes](https://www.medicalnewstoday.com/content-series/through-my-eyes) * [New Normal Health](https://www.medicalnewstoday.com/content-series/new-normal-health) Podcasts [All](https://www.medicalnewstoday.com/articles/in-conversation-podcast) * [ADHD in women: Breaking the stereotypes](https://www.medicalnewstoday.com/articles/adhd-women-breaking-stereotypes-masking-attention-disorder) * [Is sleep the missing piece in mental health?](https://www.medicalnewstoday.com/articles/is-sleep-the-missing-piece-in-mental-health) * [Artificial sweeteners and brain aging: What we know so far](https://www.medicalnewstoday.com/articles/artificial-sweeteners-and-brain-aging-what-we-know-so-far) * [Does the Mediterranean diet hold the key to longevity?](https://www.medicalnewstoday.com/articles/does-the-mediterranean-diet-hold-the-key-to-longevity) * [AMA: Registered dietitian answers 5 key questions about fiber and weight loss](https://www.medicalnewstoday.com/articles/can-fiber-help-lose-weight-dietitian-answers-5-key-questions) * [Health misinformation and disinformation: How to avoid it](https://www.medicalnewstoday.com/articles/health-misinformation-and-disinformation-how-to-avoid-it) * Tools General Health * [Drugs A-Z](https://www.medicalnewstoday.com/drugs) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Newsletter](https://www.medicalnewstoday.com/newsletter) * [Medicare Plans by State](https://www.medicalnewstoday.com/about/health-medicare-state-coverage) Health Tools * [Find a Doctor](https://connect.medicalnewstoday.com/) * [BMI Calculators and Charts](https://www.medicalnewstoday.com/articles/323586) * [Blood Pressure Chart: Ranges and Guide](https://www.medicalnewstoday.com/articles/327077) * [Breast Cancer: Self-Examination Guide](https://www.medicalnewstoday.com/articles/316898) * [Sleep Calculator](https://www.medicalnewstoday.com/articles/sleep-calculator) Quizzes * [RA Myths vs Facts](https://www.medicalnewstoday.com/articles/science-fact-or-fiction-separating-ra-myths-from-facts#1) * [Type 2 Diabetes: Managing Blood Sugar](https://www.medicalnewstoday.com/articles/managing-blood-sugar-type-2-diabetes-quiz#1) * [Ankylosing Spondylitis Pain: Fact or Fiction](https://www.medicalnewstoday.com/articles/complementary-therapies-for-as-quiz#1) * Connect About Medical News Today * [Who We Are](https://www.medicalnewstoday.com/about) * [Our Editorial Process](https://www.medicalnewstoday.com/articles/process) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Conscious Language](https://www.medicalnewstoday.com/about/conscious-language) Find Community * [Bezzy Breast Cancer](https://www.bezzybc.com/lp/2/?verzenio&utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy MS](https://www.bezzyms.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Migraine](https://www.bezzymigraine.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Psoriasis](https://www.bezzypsoriasis.com/?utm_source=mnt&utm_medium=nav-bar-connect) Follow Us [](https://www.facebook.com/MedicalNewsToday/)[](https://x.com/mnt)[](https://www.instagram.com/medicalnewstoday/)[](https://www.linkedin.com/company/mednewstoday/?originalSubdomain=ec)[](https://flipboard.com/@MedNewsToday) Subscribe # Can GLP-1s really help treat PMOS? Experts answer 3 key questions ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2020/06/500x500_Maria_Cohut.png?w=105&h=105) Written by Maria Cohut, Ph.D. on August 26, 2026 — Fact checked by Jill Seladi-Schulman, Ph.D. ![close-up of woman self-administering GLP-1 injection into the abdomen with a pen syringe](https://media.post.rvohealth.io/wp-content/uploads/sites/3/2026/08/getty_2251337475_header_1296x728-1024x575.jpg)[Share on Pinterest](https://www.pinterest.com/pin/create/button/?url=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fcan-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions&media=https%3A%2F%2Fmedia.post.rvohealth.io%2Fwp-content%2Fuploads%2Fsites%2F3%2F2026%2F08%2Fgetty_2251337475_header_1296x728-1024x575.jpg&description=PMOS%3A%20In%20what%20cases%20might%20GLP-1s%20aid%20treatment%3F "Share on Pinterest")Two medical doctors answer the most asked questions about using GLP-1s for the treatment of PMOS. Iuliia Burmistrova/ Getty Images * **Some recent evidence suggests that GLP-1 receptor agonists, used in the treatment of type 2 diabetes, may also help manage polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).** * **A small study has found that GLP-1s can lead to weight loss in people with obesity and PMOS and that, as a consequence, aspects of reproductive system health also improved.** * **The evidence, however, remains mixed.** * **A gynecologic oncologist and a family doctor specializing in weight management explain how and why GLP-1s might help with PMOS, and who might reap the most benefits.** GLP-1 receptor agonists, known as GLP-1s, for short, are a class of drugs used in the treatment of type 2 diabetes and, in some cases, obesity. Examples of commonly used [GLP-1 drugsTrusted Source](https://www.ncbi.nlm.nih.gov/books/NBK551568/) include [Ozempic](https://www.medicalnewstoday.com/articles/drugs-ozempic) and [Wegovy](https://www.medicalnewstoday.com/articles/drugs-wegovy-side-effects), which contain the active ingredient semaglutide, and [Mounjaro](https://www.medicalnewstoday.com/articles/drugs-mounjaro) and [Zepbound](https://www.medicalnewstoday.com/articles/drugs-zepbound), which contain tirzepatide. All of these can be used in the treatment [type 2 diabetes](https://www.medicalnewstoday.com/articles/317462), but only [Wegovy](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf) and [Zepbound](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf) have received Food and Drug Administration (FDA) approval in the management of obesity, while Ozempic and Mounjaro are more often used specifically in the management of diabetes. These diabetes medications can help with weight management because obesity and diabetes are often interlinked, as many people with obesity [also develop type 2 diabetes](https://www.sciencedirect.com/science/article/abs/pii/S0168822723005363). What is perhaps more surprising is that some recent studies have suggested that GLP-1s could also help with some medical conditions affecting the female reproductive system, particularly [polyendocrine metabolic ovarian syndrome (PMOS)](https://www.medicalnewstoday.com/articles/326185), formerly known as [polycystic ovary syndrome (PCOS)](https://www.medicalnewstoday.com/articles/pcos-to-pmos-how-name-change-set-to-improve-care). PMOS is characterized by irregular periods, hormonal imbalances that can present in many different ways, including through unusual hair growth, the development of fluid-filled cysts on the ovaries, and it can [co-occur with other metabolic conditions](https://pmc.ncbi.nlm.nih.gov/articles/PMC10996169/), including obesity. ## What is the evidence that GLP-1s can help with PMOS? One small study published in the [Journal of Clinical Medicine](https://www.mdpi.com/2077-0383/15/13/5165) in July 2026 found that taking GLP-1s might help not just with weight management, but also with restoring ovulatory cycles in people with PMOS. This study followed 96 individuals with PMOS, who had a [body mass index (BMI)](https://www.medicalnewstoday.com/articles/323586) greater than 25 kilograms per square meter (kg/m2), falling in the [BMI range of overweightTrusted Source](https://www.who.int/health-topics/obesity#tab=tab_1) or obesity. The participants received an individualized semaglutide treatment over a period of 6 months, with the treatment dose increased as necessary. **At the end of this intervention, 95% of participants with PMOS and overweight or mild obesity were able to regulate their menstrual cycles. However, only 25% of participants with moderate or severe obesity achieved the same positive effects.** A systematic review and meta-analysis published in the [European Journal of Endocrinology](https://academic.oup.com/ejendo/article/194/3/S25/8488941?login=false) in February 2026 stressed that the evidence suggesting that GLP-1s can aid in the treatment of PMOS remains mixed and uncertain. The meta-analysis looked at 17 articles that were relevant to the discussion, assessing data from 11 [randomized controlled trials](https://www.medicalnewstoday.com/articles/280574) between them. “This rigorous systematic review and meta-analysis show that overweight or obese individuals with PCOS, similar to those with obesity or overweight without this diagnosis, are likely to lose weight following a relatively short course of treatment,” the review authors wrote. “However, the impact of GLP-1-RAs on other metabolic outcomes in women with PCOS [PMOS] remains uncertain,” they cautioned. To shed more light on whether GLP-1s are actually a helpful course of treatment in PMOS, and who might benefit the most from this potential addition, _Medical News Today_ spoke with [Clare Thompson](https://www.cadoganclinic.com/about-us/our-consultants/dr-clare-thompson/), MBBS, a general practitioner at the Cadogan Clinic in London, United Kingdom, who leads their Weight Management Service. _MNT_ also spoke with [Steven Vasilev](https://lotusendo.com/dr-steven-vasilev-md), MD, a gynecologic oncologist specializing in [endometriosis](https://www.medicalnewstoday.com/articles/149109) and founder of the Lotus Endometriosis Institute in Santa Monica, CA. ### Why might GLP-1s help treat PMOS? Both Thompson and Vasilev explained that PMOS shares several metabolic pathways with conditions like diabetes and obesity. “PMOS is a condition [characterized](https://www.medicalnewstoday.com/articles/pcos-symptoms) by hyperandrogenism [overly high levels of the androgen hormone] and [hyperinsulinemia](https://www.medicalnewstoday.com/articles/326359) [high insulin], which can interrupt endocrine pathways involved in regular ovulation,” Thompson told us. Then, there are the mechanisms affecting ovulation in PMOS, she added: “Peripheral fatty tissue is a store of [estrogen](https://www.medicalnewstoday.com/articles/277177). Excessive levels of estrogen can interfere with the feedback cycle needed for ovulation from the ovaries. This is seen commonly in PMOS patients who may often be overweight.” That is why weight-loss strategies and GLP-1 treatments may help, said Thompson and Vasilev. > “Modest weight loss can correct the peripheral estrogen excess in fat stores, which then may help regulate ovulation. Additionally, use of GLP-1s can help regulate a PMOS patient’s [glycemic control](https://www.medicalnewstoday.com/articles/320738) [blood sugar control] and [insulin sensitivity](https://www.medicalnewstoday.com/articles/323027).” > – Clare Thompson, MBBS “Reduced hyperinsulinemia raises [sex hormone binding globulin (SHBG)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12109167/) and lowers ovarian androgen output,” Vasilev explained, because “hyperinsulinemia [suppresses](https://pmc.ncbi.nlm.nih.gov/articles/PMC10751361/) hepatic SHBG synthesis and augments ovarian androgen production, so restoring insulin sensitivity works through both hepatic and ovarian routes to lower bioavailable androgen.” However, he cautioned that, while “the evidence is promising [it] certainly does not yet support GLP-1 RAs as a first-line, disease-modifying therapy or as a blanket add-on for everyone” with PMOS. ### Should everyone with PMOS consider adding GLP-1 medication to their treatment? Thompson expanded on that point, noting that “not all patients with PMOS are overweight and in fact there is a phenotype of thin patients who do not neatly fit into the classic presentation.” “PMOS is a spectrum of symptoms and for patients who are affected at the milder end of the spectrum diet and lifestyle interventions may be enough to be helpful in managing their condition,” she advised. **Both Thompson and Vasilev stressed that only individuals with both overweight or obesity and PMOS are the most likely to benefit from a GLP-1 treatment.** “The strongest data [regarding GLP-1s for PMOS] are in overweight/obese women,” Vasilev reiterated. He also emphasized that there are several situations in which individuals with PMOS who might otherwise benefit from GLP-1 treatment would be best advised to try a different route. Firstly, he said, anyone looking to conceive should avoid GLP-1s. These drugs “are ‘teratogenicity-concern’ agents, which means that they must be stopped before conception,” said Vasilev. “This is a major caveat in a population where many patients are actively seeking fertility; contraception and preconception discontinuation counseling are required,” he advised. He also outlined the importance of gastrointestinal adverse effects such as nausea, vomiting, and dizziness, that can come with GLP-1 use. These adverse effects “are common and should not be taken lightly,” cautioned Vasilev. Moreoever, “tirzepatide’s delayed gastric emptying can [reduce oral contraceptive efficacy](https://pubmed.ncbi.nlm.nih.gov/40906565/), which is relevant when pregnancy prevention matters,” he told us, adding that “this represents a big caution flag.” Finally, Vasilev explained that since there is currently no definitive proof that GLP-1s are a potent treatment for PMOS due to “low to very low” certainty evidence derived from “small and heterogeneous” clinical trials, other treatments remain the preferred first-line of action. Thus, he said: > “Guideline positioning still focus[es] on lifestyle optimization, [combined oral contraceptives](https://www.medicalnewstoday.com/articles/322629) for menstrual/androgenic symptoms, and [metformin](https://www.medicalnewstoday.com/articles/metformin-oral-tablet) for metabolic features; GLP-1 RAs are not [an] established first-line [treatment for PMOS]. Well-designed, PMOS-specific, phenotype-stratified trials are needed before that changes.” ### Should people with other conditions affecting the reproductive system consider GLP-1 use? Another question that remains unanswered is: If GLP-1s may help some people with PMOS, could they also help individuals affected by other medical conditions of the female reproductive system? “This is where the concept plausibly spills over,” said Vasilev, “though the data are even more sparse.” **In Thompson’s view, there may be a case to be made for using GLP-1s to support people with[metabolic syndrome](https://www.medicalnewstoday.com/articles/263834) who do not experience regular ovulation as they should.** “Patients with metabolic syndrome may also benefit from use of a GLP-1, as additional peripheral fat is a store of estrogen, which could cause anovulation,” she explained. For other, more specific reproductive system conditions, however, there is hope that GLP-1s could aid treatment but the evidence remains inconclusive. “GLP-1 receptors are distributed throughout the reproductive tract, and [preclinical work](https://academic.oup.com/jcem/article/110/11/3009/8200956?login=false) attributes anti-inflammatory and anti-fibrotic effects in the gonads and endometrium, plus favorable immunomodulation [immune response regulation],” Vasilev explained. “Active investigation extends to infertility, recurrent pregnancy loss, and [endometrial hyperplasia](https://www.medicalnewstoday.com/articles/cystic-endometrial-hyperplasia),” he added. According to Vasilev: > “Endometriosis is a logical next frontier for this same reasoning. It is fundamentally a chronic inflammatory, estrogen-dependent, fibrotic disease, and the anti-inflammatory/anti-fibrotic endometrial actions ascribed to GLP-1 signaling could, in principle, extend into it.” Still, doctors would not be able to recommend GLP-1s for endometriosis at the current time, as “there is no clinical trial data supporting” this indication, said Vasilev. “So any benefit there remains hypothetical rather than evidence-based.” * [Diabetes](https://www.medicalnewstoday.com/categories/diabetes) * [Type 2](https://www.medicalnewstoday.com/diabetes/type-2) * [Obesity / Weight Loss / Fitness](https://www.medicalnewstoday.com/categories/fitness-obesity) * [Women's Health / Gynecology](https://www.medicalnewstoday.com/catego
## Related Clinical Research

- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.